Smith M L, Martin W, McKillop J H, Fogelman I
Eur J Nucl Med. 1984;9(11):519-20. doi: 10.1007/BF00263258.
In two patients with metastatic disease more lesions were detected on scintigraphs obtained with the 'low uptake' bone-scanning agent dimethyl-amino-diphosphonate. The results in these two patients provide practical support for the suggestion that bone-scanning agents with low uptake in normal bone, but high tumour-to-normal bone ratios, will allow better delineation of focal bone abnormalities.
